Host genome, epigenome, and oral microbiome interactions: Toward personalized periodontal therapy

Journal of Periodontology

Volumn 84, Issue 9, 2013, Pages 1266-1271

  Razzouk, Sleiman ^a   Termechi, Omid ^a  

^a NEW YORK UNIVERSITY COLLEGE OF DENTISTRY   (United States)

Author keywords

Epigenomics; Genome; Individualized medicine; Metagenome; Periodontal diseases; Pharmacogenetics

Indexed keywords

BACTERIUM; CLASSIFICATION; GENETIC EPIGENESIS; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; HOST PATHOGEN INTERACTION; HUMAN; HUMAN GENOME; METHODOLOGY; MICROBIOLOGY; MICROFLORA; MOUTH; PERIODONTAL DISEASE; PERSONALIZED MEDICINE; PHYSIOLOGY; REVIEW;

BACTERIA; EPIGENESIS, GENETIC; GENE-ENVIRONMENT INTERACTION; GENOME, HUMAN; HOST-PATHOGEN INTERACTIONS; HUMANS; INDIVIDUALIZED MEDICINE; MICROBIOTA; MOUTH; PERIODONTAL DISEASES;

EID: 84883430688     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2012.120531     Document Type: Review

References (62)

1. Schäfer AS, Jepsen S, Loos BG. Periodontal genetics: A decade of genetic association studies mandates better study designs. J Clin Periodontol 2011;38:103-107.
2. Laine ML, Crielaard W, Loos BG. Genetic susceptibility to periodontitis. Periodontol 2000 2012;58: 37-68.
3. Kornman KS. Mapping the pathogenesis of periodontitis: A new look. J Periodontol 2008; 79(Suppl. 8)1560-1568.
4. Grant MM. What do 'omic technologies have to offer periodontal clinical practice in the future? J Periodontal Res 2012;47:2-14.
5. Chen R, Mias GI, Li-Pook-Than J, et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 2012;148:1293-1307.
6. Belle DJ, Singh H. Genetic factors in drug metabolism. Am Fam Physician 2008;77:1553-1560.
7. Ma JD, Lee KC, Kuo GM. Clinical application of pharmacogenomics. J Pharm Pract 2012;25:417-427.
8. Würtz M, Kristensen SD, Hvas AM, Grove EL. Pharmacogenetics of the antiplatelet effect of aspirin. Curr Pharm Des 2012;18:5294-5308.
9. Fernandez Robles CR, Degnan M, Candiotti KA. Pain and genetics. Curr Opin Anaesthesiol 2012;25:444-449.
10. Shin J. Clinical pharmacogenomics of warfarin and clopidogrel. J Pharm Pract 2012;25:428-438.
11. Slots J. Herpesviral-bacterial interactions in periodontal diseases. Periodontol 2000 2010;52:117-140.
12. Kuramitsu HK, He X, Lux R, Anderson MH, Shi W. Interspecies interactions within oral microbial communities. Microbiol Mol Biol Rev 2007;71:653-670.
13. Li K, Bihan M, Yooseph S, Methé BA. Analyses of the microbial diversity across the human microbiome. PLoS ONE 2012;7:e32118.
14. Ursell LK, Clemente JC, Rideout JR, Gevers D, Caporaso JG, Knight R. The interpersonal and intrapersonal diversity of human-associated microbiota in key body sites. J Allergy Clin Immunol 2012;129: 1204-1208.
15. Zaura E, Keijser BJ, Huse SM, Crielaard W. Defining the healthy "core microbiome" of oral microbial communities. BMC Microbiol 2009;9:259-271.
16. Pflughoeft KJ, Versalovic J. Human microbiome in health and disease. Annu Rev Pathol 2012;7:99-122.
17. Liu B, Faller LL, Klitgord N, et al. Deep sequencing of the oral microbiome reveals signatures of periodontal disease. PLoS ONE 2012;7:e37919.
18. Kumar PS, Mason MR, Brooker MR, O'Brien K. Pyrosequencing reveals unique microbial signatures associated with healthy and failing dental implants. J Clin Periodontol 2012;39:425-433.
19. Offenbacher S, Barros SP, Beck JD. Rethinking periodontal inflammation. J Periodontol 2008; 79(Suppl. 8)1577-1584.
20. Benson AK, Kelly SA, Legge R, et al. Individuality in gut microbiota composition is a complex polygenic trait shaped by multiple environmental and host genetic factors. Proc Natl Acad Sci U S A 2010;107:18933-18938.
21. Virgin HW, Todd JA. Metagenomics and personalized medicine. Cell 2011;147:44-56.
22. Spor A, Koren O, Ley R. Unravelling the effects of the environment and host genotype on the gut microbiome. Nat Rev Microbiol 2011;9:279-290.
23. Diaz PI. Microbial diversity and interactions in subgingival biofilm communities. Front Oral Biol 2012;15:17-40.
24. NIH Human Microbiome Project. HMP project catalog. Available at: http://www.hmpdacc-resources.org/hmp-catalog/main.cgi?section=Home&page= Home.Accessed May 15, 2012.
25. Integrated Microbial Genomes/Human Microbiome Project (IMG/HMP). HMP genomes and samples. Available at: http://www.hmpdacc-resources.org/ cgi-bin/imgm-hmp/main.cgi. Accessed May 16, 2012.
26. Human Oral Microbiome Database. Available at: http://www.homd.org. Accessed on May 16, 2012.
27. Belda-Ferre P, Alcaraz LD, Cabrera-Rubio R, et al. The oral metagenome in health and disease. ISME J 2012;6:46-56.
28. Mathers JC, Strathdee G, Relton CL. Induction of epigenetic alterations by dietary and other environmental factors. Adv Genet 2010;71:3-39.
29. Wilson AG. Epigenetic regulation of gene expression in the inflammatory response and relevance to common diseases. J Periodontol 2008; 79(Suppl. 8):1514-1519.
30. Dawson MA, Kouzarides T. Cancer epigenetics: From mechanism to therapy. Cell 2012;150:12-27.
31. García MP, García-García A. Epigenome and DNA methylation in oral squamous cell carcinoma. Methods Mol Biol 2012;863:207-219.
32. Gomez RS, Dutra WO, Moreira PR. Epigenetics and periodontal disease: Future perspectives. Inflamm Res 2009;58:625-629.
33. Barros SP, Offenbacher S. Epigenetics: Connecting environment and genotype to phenotype and disease. J Dent Res 2009;88:400-408.
34. Cantley MD, Bartold PM, Marino V, et al. Histone deacetylase inhibitors and periodontal bone loss. J Periodontal Res 2011;46:697-703.
35. Fitzpatrick DR, Wilson CB. Methylation and demethylation in the regulation of genes, cells, and responses in the immune system. Clin Immunol 2003;109:37-45.
36. McCall CE, Yoza B, Liu T, El Gazzar M. Genespecific epigenetic regulation in serious infections with systemic inflammation. J Innate Immun 2010;2: 395-405.
37. Reiner SL. Epigenetic control in the immune response. Hum Mol Genet 2005;14 (Spec. No. 1):R41-R46.
38. Viana MB, Cardoso FP, Diniz MG, et al. Methylation pattern of IFN-g and IL-10 genes in periodontal tissues. Immunobiology 2011;216:936-941.
39. De Oliveira NF, Andia DC, Planello AC, et al. TLR2 and TLR4 gene promoter methylation status during chronic periodontitis. J Clin Periodontol 2011;38:975-983.
40. Zhang S, Crivello A, Offenbacher S, Moretti A, Paquette DW, Barros SP. Interferon-gamma promoter hypomethylation and increased expression in chronic periodontitis. J Clin Periodontol 2010;37:953-961.
41. Delgado-Calle J, Sañudo C, Fernández AF, García-Renedo R, Fraga MF, Riancho JA. Role of DNA methylation in the regulation of the RANKL-OPG system in human bone. Epigenetics 2012;7:83-91.
42. Holroyd C, Harvey N, Dennison E, Cooper C. Epigenetic influences in the developmental origins of osteoporosis. Osteoporos Int 2012;23:401-410.
43. NIH Roadmap Epigenomics Mapping Consortium. Complete epigenomes. Available at: http:/www.roadmapepigenomics. org. Accessed on May 21, 2012.
44. Ulfgren AK, Gröndal L, Lindblad S, et al. Interindividual and intra-articular variation of proinflammatory cytokines in patients with rheumatoid arthritis: Potential implications for treatment. Ann Rheum Dis 2000;59: 439-447.
45. de Maat MP, de Bart AC, Hennis BC, et al. Interindividual and intraindividual variability in plasma fibrinogen, TPA antigen, PAI activity, and CRP in healthy, young volunteers and patients with angina pectoris. Arterioscler Thromb Vasc Biol 1996;16:1156-1162.
46. Shen J, Ordovas JM. Impact of genetic and environmental factors on hsCRP concentrations and response to therapeutic agents. Clin Chem 2009;55:256-264.
47. Takashiba S, Naruishi K. Gene polymorphisms in periodontal health and disease. Periodontol 2000 2006; 40:94-106.
48. International HapMap Project. HapMap genome browser. Available at: http://hapmap.ncbi.nlm.nih.gov/cgi-perl/ gbrowse/hapmap28-B36/. Accessed June 2, 2012.
49. 1000 Genomes. Available at: http://www.1000genomes. org. Accessed June 5, 2012.
50. Personalized Medicine Coalition. Available at: http:// www.personalizedmedicinecoalition.org. Accessed February 12, 2012.
51. Roshandel D, Holliday KL, Pye SR, et al; EMAS Study Group. Genetic variation in the RANKL/RANK/OPG signaling pathway is associated with bone turnover and bone mineral density in men. J Bone Miner Res 2010;25:1830-1838.
52. Tsuchida S, Satoh M, Umemura H, et al. Proteomic analysis of gingival crevicular fluid for discovery of novel periodontal disease markers. Proteomics 2012; 12:2190-2202.
53. Baliban RC, Sakellari D, Li Z, DiMaggio PA, Garcia BA, Floudas CA. Novel protein identification methods for biomarker discovery via a proteomic analysis of periodontally healthy and diseased gingival crevicular fluid samples. J Clin Periodontol 2012;39:203-212.
54. Glurich I, Acharya A, Shukla S, Nycz G, Brilliant M. The oral-systemic personalized medicine model at Marshfield Clinic. Oral Dis 2013;19:1-17.
55. S. 3822 (109th): Genomics and Personalized Medicine Act of 2006. Available at: http://www.govtrack.us/ congress/bills/109/s3822/text. Accessed June 6, 2012.
56. Publications Office of the European Union. Biobanks for Europe, a challenge for governance. Available at: http://bookshop.europa.eu/en/biobanks- for-europepbKINA25302/. Accessed June 8, 2012.
57. Mi Q, Li NY, Ziraldo C, et al. Translational systems biology of inflammation: Potential applications to personalized medicine. Per Med 2010;7:549-559.
58. Vodovotz Y, Constantine G, Faeder J, et al. Translational systems approaches to the biology of inflammation and healing. Immunopharmacol Immunotoxicol 2010;32:181-195.
59. Scott SA. Personalizing medicine with clinical pharmacogenetics. Genet Med 2011;13:987-995.
60. Pharmacogenomics Research Network. Available at: http://www.pgrn.org/. Accessed December 5, 2011.
61. The Pharmacogenomics Knowledgebase. Available at: http://www.pharmgkb. org/. Accessed December 5, 2011.
62. Food and Drug Administration. Guidance for Industry. Clinical Pharmacogenomics: Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling. Available at: http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM337169. pdf. Accessed August 31, 2012.